MARKET

RENB

RENB

Renovaro
NASDAQ
1.130
-0.070
-5.83%
After Hours: 1.170 +0.04 +3.54% 19:42 05/10 EDT
OPEN
1.190
PREV CLOSE
1.200
HIGH
1.260
LOW
1.130
VOLUME
189.68K
TURNOVER
0
52 WEEK HIGH
5.25
52 WEEK LOW
0.3928
MARKET CAP
162.35M
P/E (TTM)
-1.6496
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RENB last week (0429-0503)?
Weekly Report · 5d ago
RenovaroCube, Wholly Owned Subsidiary Of Renovaro, Unveils Flamingo, A Multi-Cancer Detection Model Contributing To Its Mission To Transform Early Cancer Diagnostics
RenovaroCube, a company at the forefront of AI-driven healthcare innovation, unveils Flamingo, a potentially groundbreaking multi-cancer detection model. The model uses ultra-low pass whole genome sequencing of cell-free DNA to identify cancer at an early stage. Traditional cancer detection methods often fall short in identifying cancers early.
Benzinga · 04/30 15:22
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
RenovaroCube, a company at the forefront of AI-driven healthcare innovation, unveils Flamingo, a potentially groundbreaking multi-cancer detection model. The technology is designed to transform early cancer diagnostics. It uses ultra-low pass whole genome sequencing of cell-free DNA to detect cancer.
Barchart · 04/30 10:00
Weekly Report: what happened at RENB last week (0422-0426)?
Weekly Report · 04/29 10:58
Applied Dna Sciences, OptimizeRx, SCWorx among healthcare movers
Seeking Alpha · 04/26 14:00
RenovaroCube to acquire 100% ownership of Cyclomics
Healthcare RenovaroCube to acquire 100% ownership of Cyclomics. Oxford Nanopore and Nvidia will be key partners in early cancer diagnostics and monitoring of treatment efficacy.  Renovaro Inc. Has entered into an amendment to its letter of intent to acquire full ownership of cyclomics.
Seeking Alpha · 04/24 13:40
*Renovaro Amends Binding Letter of Intent To Acquire 100% Ownership of Cyclomics >RENB
Dow Jones · 04/24 13:02
RenovaroCube To Acquire 100% Ownership Of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership; Financial Terms Not Disclosed
Renovaro Inc. And Cyclomics announce a significant milestone in their collaboration. RenovaroCube will acquire 100% ownership of Cyclomics. Cyclomics is a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore and Nvidia will provide super computing power for the company.
Benzinga · 04/24 13:01
More
About RENB
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Webull offers Renovaro Inc stock information, including NASDAQ: RENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RENB stock methods without spending real money on the virtual paper trading platform.